BP

534

-1.12%↓

BP

534

-1.12%↓

BP

534

-1.12%↓

BP

534

-1.12%↓

BP

534

-1.12%↓

Home・Aandelen Lijst・Smith & Nephew PLC
Search

Smith & Nephew PLC

Open

1,148 1.23

Buy

Prijsupdate 1 mei 2026, 15:29 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1146

Max

1154

Belangrijke statistieken

By Trading Economics

Inkomsten

47M

342M

Verkoop

318M

3.3B

K/W

Sectorgemiddelde

21.642

63.079

EPS

0.429

Dividendrendement

3.44

Winstmarge

10.36

Werknemers

16,988

EBITDA

162M

886M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+26.67% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.44%

3.27%

Volgende Winsten

4 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.4B

9.8B

Vorige openingsprijs

1146.77

Vorige sluitingsprijs

1148

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 mei 2026, 23:58 UTC

Winsten

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

DJ

Lezen

7 mei 2026, 22:57 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

DJ

Lezen

7 mei 2026, 23:52 UTC

Winsten

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

DJ

Lezen

7 mei 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

DJ

Lezen

7 mei 2026, 23:39 UTC

Marktinformatie

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

DJ

Lezen

7 mei 2026, 23:28 UTC

Marktinformatie

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

DJ

Lezen

7 mei 2026, 23:11 UTC

Winsten

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

DJ

Lezen

7 mei 2026, 23:06 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

DJ

Lezen

7 mei 2026, 23:05 UTC

Winsten

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

DJ

Lezen

7 mei 2026, 23:04 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

DJ

Lezen

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

DJ

Lezen

7 mei 2026, 23:03 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

DJ

Lezen

7 mei 2026, 23:02 UTC

Winsten

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

DJ

Lezen

7 mei 2026, 23:00 UTC

Marktinformatie

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

DJ

Lezen

7 mei 2026, 22:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lezen

7 mei 2026, 22:45 UTC

Marktinformatie

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

DJ

Lezen

7 mei 2026, 22:42 UTC

Winsten

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

DJ

Lezen

7 mei 2026, 22:33 UTC

Winsten
Acquisities, Fusies, Overnames

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

DJ

Lezen

7 mei 2026, 22:32 UTC

Winsten

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

DJ

Lezen

7 mei 2026, 22:31 UTC

Winsten

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

DJ

Lezen

7 mei 2026, 22:31 UTC

Winsten

Macquarie: 68% of FY Income From International >MQG.AU

DJ

Lezen

7 mei 2026, 22:30 UTC

Winsten

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

DJ

Lezen

7 mei 2026, 22:30 UTC

Winsten

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

DJ

Lezen

7 mei 2026, 22:29 UTC

Winsten

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

DJ

Lezen

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

DJ

Lezen

7 mei 2026, 22:28 UTC

Winsten

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

DJ

Lezen

7 mei 2026, 22:27 UTC

Winsten

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

DJ

Lezen

7 mei 2026, 22:27 UTC

Winsten

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

DJ

Lezen

7 mei 2026, 22:26 UTC

Winsten

Macquarie to End Share Buyback Extended in November>MQG.AU

DJ

Lezen

7 mei 2026, 22:25 UTC

Winsten

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

26.67% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,411.1 GBX  26.67%

Hoogste 1,700 GBX

Laagste 958.684 GBX

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

3

Hold

0

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Smith & Nephew PLC - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Andere aandelen uit de sector

BPUS

BP PLC ADR

534

↓-1.12%
help-icon Live chat